Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU6 in Overweight or Obese Subjects with Type 2 Diabetes
NCT06104358Phase 2Withdrawn
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing Active Treatment HU6 with Placebo (2 arms). Primary endpoint: Sleeping Metabolic Rate change from Baseline at 26 weeks. Planned start Nov 2023; status: withdrawn.
02
Drugs
HU6
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06104358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104358.